What Guardant Health Is and What It Does
Guardant Health is a Silicon Valley–based precision oncology company that develops blood-based tests to detect and monitor cancer. Founded in 2012, the company has built its reputation on a single core idea: that a routine blood draw can reveal information about tumors without the need for an invasive tissue biopsy. Its tests analyze circulating tumor DNA, or ctDNA, fragments that tumors shed into the bloodstream. This approach, commonly called a liquid biopsy, has become one of the most actively researched areas in oncology over the past decade.
More from this site
Keep reading the latest coverage
Guardant offers several products aimed at different points along the cancer care journey. The company's Guardant360 test is designed to look for genomic alterations across hundreds of cancer-related genes in advanced solid tumors, providing oncologists with a molecular profile that can help guide treatment decisions. GuardantOMNISearch expands on this by enabling broader biomarker discovery. For early detection, Guardant has developed the Shield test, which aims to identify colorectal cancer in asymptomatic individuals. Each product targets a different clinical need, from treatment selection to screening.
How Guardant's Liquid Biopsy Technology Works
The technology behind Guardant's tests relies on next-generation sequencing and advanced bioinformatics. When a tumor grows, cells die and release DNA into the blood. Guardant's assays isolate cell-free DNA from a plasma sample and use proprietary sequencing chemistry to identify mutations, copy number changes, and other genomic signatures associated with cancer. Because the test looks for fragments originating specifically from tumors, it can distinguish cancer-related signals from the background noise of normal cell-free DNA.
The laboratory process involves drawing a standard blood sample, typically from a vein in the arm, and shipping it to Guardant's CLIA-certified and CAP-accredited laboratory. Results are usually returned within a few weeks, depending on the specific test and the clinician's ordering workflow. The company emphasizes that its tests are intended to complement, not replace, traditional tissue biopsies and imaging, and that results should always be interpreted in the context of a patient's full clinical picture.
Clinical Use and Evidence Behind the Tests
Guardant360 has been studied in multiple clinical settings, including retrospective and prospective cohorts, and is used by oncologists in the United States and internationally for patients with advanced cancers. The test can identify actionable mutations in genes such as EGFR, KRAS, BRAF, and others, which may inform the use of targeted therapies or clinical trial enrollment. Guardant has published data in peer-reviewed journals and presented findings at major oncology conferences, including the American Society of Clinical Oncology annual meeting.
For early detection, Guardant has focused on colorectal cancer with its Shield test. Colorectal cancer is one of the leading causes of cancer death, and early detection significantly improves outcomes. Shield aims to detect cancer and advanced precancerous lesions through a blood draw, offering an alternative to colonoscopy for patients who are unwilling or unable to undergo that procedure. The company has published data from clinical studies to support Shield's performance characteristics, though it is important to note that no screening test is perfect, and positive results typically require follow-up with standard diagnostic methods.
Access, Cost, and Practical Considerations
Access to Guardant tests depends on several factors, including the specific product, the patient's diagnosis, and the prescribing clinician's judgment. In the United States, Guardant works with major commercial insurance plans, Medicare, and Medicaid, and offers a patient assistance program for those who may face financial barriers. Coverage varies by payer and clinical indication, so patients are encouraged to verify benefits before testing.
The cost of Guardant testing can vary widely depending on the test ordered and the patient's insurance coverage. Guardant provides cost transparency tools and financial counseling support. From a practical standpoint, the test requires only a blood draw, which makes it less burdensome than a tissue biopsy, but turnaround times and the need for a clinician to order and interpret the results remain important considerations.
Limitations and What the Company Does Not Claim
Guardant's tests are not meant to be used as stand-alone screening tools for the general population, and they are not approved to diagnose cancer on their own. No liquid biopsy test currently available can replace the diagnostic gold standard of tissue biopsy with histopathological examination. False-positive and false-negative results are possible, and clinical decisions should never rely solely on a blood-based assay.
The company also does not claim that its tests can detect all cancers or all stages of disease with equal sensitivity. Performance varies by cancer type, stage, and the biological characteristics of the tumor. Patients should discuss the potential benefits and limitations of any Guardant test with their oncologist or primary care provider to determine whether it is appropriate for their specific situation.
Guardant's Role in the Broader Precision Oncology Landscape
Guardant operates in a competitive field that includes other companies developing liquid biopsy and molecular profiling technologies. Its main differentiators include a proprietary sequencing chemistry platform, a large clinical database, and a focus on building tests that integrate into routine oncology workflows. The company has also invested in partnerships with pharmaceutical firms and research institutions to expand the clinical evidence base for its products.
For patients, Guardant represents one option among many for genomic profiling and, increasingly, early cancer detection. The landscape of blood-based cancer testing continues to evolve rapidly, with new clinical data and regulatory approvals shaping which tests are used and for whom. Keeping up with peer-reviewed evidence and guidelines from organizations such as the National Comprehensive Cancer Network remains essential for clinicians and patients evaluating any liquid biopsy test.